Eli Lilly and Company (LLY) Announces New Phase 3 Trial Results for Orforglipron
This comes as a breakthrough for the company as Orforglipron is the first non-injectable GLP-1 receptor agonist to show strong results in this type of trial. The results showed that at 40 weeks, all tested doses of Orforglipron significantly lowered A1C. Moreover, the two highest doses also led to meaningful and statistically significant weight loss.
The safety profile of the drug was also consistent, as the most common side effects were mild-to-moderate stomach issues like diarrhea and nausea, mostly during dose increases. In addition, discontinuation due to side effects was similar to other drugs in this class. The company expects to share topline results from ACHIEVE-2 later this year. In this trial, Orforglipron will be compared with dapagliflozin. The company remains on track to submit Orforglipron for weight management to global regulatory agencies by the end of this year and for type 2 diabetes by 2026.
Eli Lilly and Company (NYSE:LLY) is an international pharmaceutical company that focuses on treatments for diabetes, oncology, immunology, neuroscience, and cardiometabolic health.
Advanced Micro Devices, Inc. (NASDAQ:LLY) is an international semiconductor company that designs and sells high-performance processors and graphics chips used in data centers.
While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Novo Nordisk Ramps Up U.S. Legal Fight Over Wegovy, Ozempic Copies
Novo Nordisk (NOVO, Financials) expanded its U.S. legal campaign against makers of unapproved versions of semaglutide the active ingredient in its blockbuster weight?loss and diabetes drugs Wegovy and Ozempic. The Danish drugmaker said Tuesday it filed 14 new lawsuits; the targets include telehealth providers, compounding pharmacies, and medical spas accused of selling compounded semaglutide under the fake guise of personalization. Warning! GuruFocus has detected 1 Warning Sign with NVO. The suits name firms such as Prism Aesthetics, Mochi Health, and Fella Health; some have also appeared in Eli Lilly's (LLY, Financials) litigation over knockoff versions of its weight?loss drug Zepbound. Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in some cases, the products allegedly contain illicit foreign?sourced active pharmaceutical ingredients. Compounders were temporarily allowed to produce semaglutide during a declared shortage; when the U.S. Food and Drug Administration ended that allowance, some companies shifted to offering personalized versions outside the approved drug label. Novo argues the approach violates state laws on corporate practice of medicine; it also raises safety concerns, as the copies have not been proven effective. Industry groups pushed back; Scott Brunner, CEO of the Alliance for Pharmacy Compounding, said Novo's claims misrepresent the work of legitimate, state?licensed pharmacies. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 minutes ago
- Yahoo
Trump says US will charge tariff of about 100% on semiconductor imports
WASHINGTON (Reuters) -The United States will impose a tariff of about 100% on semiconductor chips imported into the country, President Donald Trump said on Wednesday. Trump told reporters in the Oval Office that the new tariff rate would apply to "all chips and semiconductors coming into the United States," but would not apply to companies that had made a commitment to manufacture in the United States. "So 100% tariff on all chips and semiconductors coming into the United States. But if you've made a commitment to build (in the U.S.), or if you're in the process of building (in the U.S.), as many are, there is no tariff," Trump said. Sign in to access your portfolio
Forbes
7 minutes ago
- Forbes
Trump's Reciprocal Tariff Rates Will Take Effect This Week – Here's What That Means For You
Andrew Wilson, Deputy Secretary-General and Global Policy Director at the International Chamber of Commerce, joined Brittany Lewis on "Forbes Newsroom" to discuss President Trump's reciprocal tariff rates and trade agreements with dozens of nations. Watch the full interview above.
